Travere Therapeutics (TVTX) Earnings Date, Estimates & Call Transcripts $16.97 -0.21 (-1.22%) (As of 09:39 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Travere Therapeutics Latest Earnings SummaryActual EPS (Oct. 31) -$0.70 Beat By $0.01 Consensus EPS (Oct. 31) -$0.71 Travere Therapeutics issued Q3 2024 earnings on October 31, 2024, reporting an EPS of -$0.70, which topped the consensus estimate of -$0.71 by $0.01. Quarterly revenue rose 69.6% year-over-year to $62.90 million, above the consensus estimate of $60.87 million. With a trailing EPS of -$4.55, Travere Therapeutics' earnings are expected to grow next year, from ($3.94) to ($1.35) per share. Conference CallConference Call TranscriptSEC 10-Q/10-K FilingPowered by Get Travere Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Travere Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTVTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TVTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Travere Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$1.20-$0.96-$1.08Q2 20244-$1.04-$0.65-$0.89Q3 20244-$0.94-$0.67-$0.82Q4 20244-$0.80-$0.51-$0.66FY 202416-$3.98-$2.79-$3.45Q1 20251-$0.34-$0.34-$0.34Q2 20251-$0.10-$0.10-$0.10Q3 20251$0.27$0.27$0.27Q4 20252$0.30$0.54$0.42FY 20255$0.13$0.37$0.25 Travere Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails10/31/2024Q3 2024-$0.71-$0.70+$0.01-$0.70$60.87M$62.90M8/1/2024Q2 2024-$0.87-$0.90 -$0.03-$0.89$49.50M$54.12M5/6/2024Q1 2024-$0.98-$1.76 -$0.78-$1.76$43.46M$41.40M2/15/2024Q4 2023-$1.27-$1.16+$0.11-$1.14$41.25M$45.06M11/7/2023Q3 2023-$1.09-$1.17 -$0.08-$4.31$132.01M$37.10M8/3/2023Q2 2023-$1.16-$1.13+$0.03-$1.13$53.93M$59.70M Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$1.18-$1.27 -$0.09-$1.27$50.93M$56.99M2/23/2023Q4 2022-$1.04-$1.03+$0.01-$1.03$54.80M$55.87M Travere Therapeutics Earnings - Frequently Asked Questions When did Travere Therapeutics announce their last quarterly earnings? Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earning data on Thursday, October 31, 2024. Learn more on TVTX's earnings history. Did Travere Therapeutics beat their earnings estimates last quarter? In the previous quarter, Travere Therapeutics (NASDAQ:TVTX) reported ($0.70) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.71) by $0.01. Learn more on analysts' earnings estimate vs. TVTX's actual earnings. How can I listen to Travere Therapeutics's earnings conference call? The conference call for Travere Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Travere Therapeutics's conference call transcript? The conference call transcript for Travere Therapeutics's latest earnings report can be read online. Read Transcript How can I view Travere Therapeutics's earnings report? Travere Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded annual revenue of $203.45 million. How much profit does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded net income of -$111.40 million. TVTX has generated -$4.55 earnings per share over the last four quarters. What is Travere Therapeutics's EPS forecast for next year? Travere Therapeutics's earnings are expected to grow from ($3.94) per share to ($1.35) per share in the next year. More Earnings Resources from MarketBeat Related Companies TG Therapeutics Earnings Viking Therapeutics Earnings BridgeBio Pharma Earnings Crinetics Pharmaceuticals Earnings Krystal Biotech Earnings Arcellx Earnings ADMA Biologics Earnings Ultragenyx Pharmaceutical Earnings Apellis Pharmaceuticals Earnings Biohaven Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. This page (NASDAQ:TVTX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
